FDA/X
May 16, 2025, 21:18
Martin Makary Applauds FDA Clearance of First Blood Test for Alzheimer’s Diagnosis
Martin Makary, 27th Commissioner of the U.S. FDA, shared FDA’s post on X:
“Alzheimer’s disease impacts too many people, more than breast cancer and prostate cancer combined. Knowing that 10% of people aged 65 and older have Alzheimer’s, and that by 2050 that number is expected to double, I am hopeful that new medical products such as this one will help patients.”
Quoting FDA’s post:
“Today, the FDA cleared for marketing the first in vitro diagnostic device that tests blood to aid in diagnosing Alzheimer’s disease. This is for the early detection of amyloid plaques associated with Alzheimer’s disease in adult patients, aged 55 years and older, exhibiting signs and symptoms of the disease.”
More posts featuring Martin Makary.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 21, 2025, 01:40
May 20, 2025, 17:22
May 20, 2025, 16:37
May 20, 2025, 16:27